Bio-Path gets patent for nucleic acid drug platform

By The Science Advisory Board staff writers

February 10, 2021 -- The U.S. Patent and Trademark Office has granted a patent to Bio-Path Holdings for its nucleic acid drug platform, expanding protections for the company's DNAbilize technology.

Bio-Path was awarded U.S. patent No. 10,898,506 titled, "P-ethoxy nucleic acids for liposomal formulation."

On February 23, the company expects to be issued U.S. patent No. 10,927,379 for its lead product candidate prexigebersen, a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.